Canada Markets close in 6 hrs 25 mins

Akero Therapeutics, Inc. (0K4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
8.40+0.20 (+2.44%)
As of 08:00AM CEST. Market open.

Akero Therapeutics, Inc.

601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
650 487 6488
https://www.akerotx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees33

Key Executives

NameTitlePayExercisedYear Born
Dr. Andrew Cheng M.D., Ph.D.Pres, CEO & Director849.06kN/A1967
Dr. Jonathan M. YoungCo-Founder, Exec. VP, COO & Sec.621kN/A1970
Dr. Timothy RolphCo-Founder & Chief Scientific Officer621kN/A1954
Mr. William R. White J.D.Exec. VP, CFO, Treasurer & Head of Corp. Devel.614.15kN/A1973
Ms. Catriona YaleExec. VP & Chief Devel. OfficerN/AN/A1973
Mr. John J. SchembriVP of Fin. & ControllerN/AN/A1962
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate Governance

Akero Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.